Obstetric and Gynecologic Imaging

Should You Order Screening Ultrasound for Ovarian Cancer in Average-Risk Postmenopausal Women?

·
Should You Order Screening Ultrasound for Ovarian Cancer in Average-Risk Postmenopausal Women?

A 62-year-old woman presents for her annual wellness exam. She is otherwise healthy, with no new complaints. Having recently read a news article about cancer, she asks if she should have an ultrasound to “check for” ovarian cancer, noting that she has been postmenopausal for a decade. As her physician, you face a common but critical decision: should you order screening imaging for an asymptomatic, average-risk individual? This article provides a detailed clinical workflow for this specific scenario, explaining why major guidelines advise against this practice. Based on the American College of Radiology (ACR) Appropriateness Criteria, imaging for this indication, including a US color Doppler of the ovaries, is rated Usually Not Appropriate.

Who Fits This Clinical Scenario?

This guidance applies specifically to adult women who are both postmenopausal and at average risk for ovarian cancer. Defining these terms is critical to applying the recommendations correctly.

Inclusion Criteria:

  • Postmenopausal: Generally defined as 12 consecutive months without a menstrual period, in the absence of other pathological or physiological causes. This typically occurs in the late 40s or early 50s.
  • Average Risk: This refers to the general population without known major genetic predispositions or a significant family history of ovarian cancer. The vast majority of women fall into this category.

Exclusion Criteria (These patients require a different workup):

  • Symptomatic Patients: If a patient presents with new-onset pelvic pain, abdominal bloating, early satiety, or urinary urgency, this is no longer a screening scenario. It becomes a diagnostic workup, which follows a different clinical pathway.
  • High-Risk Patients: This guidance does not apply to women with a known hereditary cancer syndrome (e.g., BRCA1 or BRCA2 mutations, Lynch syndrome) or a strong family history suggesting such a syndrome. These individuals are managed under the ACR variant for high-risk screening.
  • Premenopausal Patients: The hormonal environment and the prevalence of benign, functional ovarian cysts are vastly different in premenopausal women, necessitating separate screening considerations.

What Diagnoses Are You Working Up in This Scenario?

In a screening context for an asymptomatic, average-risk individual, the primary goal is to detect epithelial ovarian cancer at an early, more treatable stage. However, the decision not to screen is based on the extremely low prevalence of the disease in this population and the high likelihood that an abnormal finding is not cancer. The “differential” for a positive screening test in this scenario is heavily skewed toward benign conditions.

Ovarian Cancer: This is the target condition. It is a relatively uncommon malignancy but has a high mortality rate, largely because it is often diagnosed at an advanced stage. The rationale for screening is to find it earlier, but evidence shows this does not ultimately improve mortality in the average-risk population.

Benign Adnexal Cysts: This is the most common finding on a pelvic ultrasound in postmenopausal women. Simple cysts are overwhelmingly benign and often require no follow-up. However, their discovery on a screening ultrasound can trigger a cascade of further imaging, specialist referrals, and patient anxiety, without providing clinical benefit.

Incidentalomas of Other Pelvic Organs: An ultrasound of the ovaries inevitably images adjacent structures. This can lead to the discovery of incidental findings unrelated to the ovaries, such as uterine fibroids, bladder diverticula, or benign vascular changes. Each of these can lead to further, often unnecessary, investigation. The core issue is that the pre-test probability of finding a clinically significant, early-stage ovarian cancer is far lower than the probability of finding a benign, clinically irrelevant abnormality that leads to harm.

Why Is Routine Imaging Not Recommended for Screening in This Scenario?

For the average-risk, postmenopausal woman, the ACR and other major medical bodies like the U.S. Preventive Services Task Force (USPSTF) conclude that the potential harms of ovarian cancer screening outweigh the benefits. Consequently, all imaging modalities for this purpose are rated Usually Not Appropriate.

The core rationale is based on large-scale clinical trials which have shown that screening with transvaginal ultrasound and/or the CA-125 blood test does not reduce ovarian cancer mortality. What it does do, however, is generate a significant number of false-positive results. These false positives lead to a cascade of negative consequences, including patient anxiety and unnecessary invasive procedures, such as oophorectomy, which carry their own surgical risks.

Let’s review the specific modalities and why they are not recommended for screening:

  • US color Doppler ovaries, US pelvis transvaginal, and US pelvis transabdominal: All are rated Usually Not Appropriate. While these studies involve no ionizing radiation (0 mSv), their high sensitivity for detecting any adnexal abnormality, most of which are benign, is the primary driver of harm. The high false-positive rate leads to a diagnostic and surgical cascade that does not translate into saved lives in this population.
  • CT abdomen and pelvis (with or without IV contrast): Also rated Usually Not Appropriate. In addition to the problems of false positives, CT exposes the patient to significant ionizing radiation (☢☢☢ to ☢☢☢☢, or 1-30 mSv). This level of radiation is not justified for a screening test with no proven mortality benefit.
  • MRI pelvis (with or without IV contrast): Rated Usually Not Appropriate. While MRI avoids radiation, it is a high-cost, resource-intensive examination. Its high sensitivity can lead to the same cascade of interventions as ultrasound, making it unsuitable for screening the general population.

The consensus is clear: for an asymptomatic, average-risk postmenopausal woman, the best imaging order is no order at all. The clinical focus should shift from ordering a test to patient education.

What’s Next? The Downstream Workflow

Since imaging is not recommended, the workflow shifts from ordering tests to patient counseling and accurate risk assessment.

  • If the Patient is Confirmed Average-Risk: The primary next step is a conversation. Explain that current evidence from major studies shows that routine screening for ovarian cancer with ultrasound or blood tests does not save lives and can lead to unnecessary surgeries and complications. Reassure the patient that this recommendation is based on protecting them from harm. Shift the focus to symptom awareness, counseling them to seek evaluation if they develop persistent bloating, pelvic or abdominal pain, difficulty eating, or urinary symptoms.
  • If the Patient’s History Suggests Higher Risk: If, during the conversation, you uncover a significant family history (e.g., multiple first- or second-degree relatives with ovarian, breast, colon, or endometrial cancer), the patient may no longer fit the “average-risk” category. The workflow then changes:

1. Stop considering this as an average-risk screening scenario.
2. Refer the patient for formal genetic counseling and potentially genetic testing (e.g., for BRCA mutations).
3. Consult the ACR Appropriateness Criteria for the Postmenopausal, High Risk scenario, as imaging recommendations are different for that population.

  • If Imaging Was Performed Inadvertently: If an ultrasound was ordered and reveals an adnexal cyst, the next step is to characterize it using a standardized system like the Ovarian-Adnexal Reporting and Data System (O-RADS). Management will depend on the O-RADS score, but this entire pathway is the iatrogenic cascade that evidence-based screening guidelines are designed to prevent.

Pitfalls to Avoid (and When to Get Help)

Navigating the decision not to screen requires careful communication and clinical judgment. Here are common pitfalls to avoid in this specific scenario:

  • Confusing Screening with Diagnosis: The recommendation against screening applies only to asymptomatic women. If a patient presents with symptoms like persistent bloating or pelvic pain, she requires a diagnostic workup, which appropriately starts with a pelvic ultrasound. Do not misapply screening guidelines to a symptomatic patient.
  • Ordering a Test to Reassure the Patient: While well-intentioned, ordering a low-value test can cause more anxiety than it relieves. A false-positive result can initiate a stressful and potentially harmful cascade of follow-up tests and procedures.
  • Incomplete Family History: A quick or superficial family history can miss critical details that would move a patient from average-risk to high-risk. Be thorough in asking about cancers in first- and second-degree relatives.
  • Ignoring Patient Concerns: Simply saying “we don’t do that” can erode trust. Acknowledge the patient’s concern, validate their desire to be proactive, and then explain the evidence-based rationale for why screening is not the best path for them.

If you uncover a complex family history or if the patient has a known genetic mutation, the best next step is to escalate care by referring them to a gynecologist or gynecologic oncologist with expertise in high-risk surveillance.

Related ACR Topics and Tools

For a comprehensive understanding of imaging for ovarian cancer screening across all patient populations, and for tools to help with ordering and patient communication, the following resources are invaluable.

Frequently Asked Questions

Why isn’t even a simple, non-radiation ultrasound recommended for screening average-risk postmenopausal women?

While ultrasound is safe and uses no radiation, its high sensitivity leads to a large number of false-positive findings. It frequently detects benign cysts, which can trigger a cascade of further imaging, specialist visits, patient anxiety, and sometimes unnecessary surgery. Large clinical trials have shown that this screening approach does not reduce deaths from ovarian cancer but does cause significant harm.

What specific family history details would move a patient from ‘average risk’ to ‘high risk’?

A patient is generally considered high-risk if they have a known genetic mutation (like BRCA1 or BRCA2), a personal history of certain cancers, or a strong family history. This includes having multiple first- or second-degree relatives with ovarian, premenopausal breast, fallopian tube, or peritoneal cancer, or a known hereditary cancer syndrome like Lynch syndrome in the family. A formal risk assessment and genetic counseling are often required to clarify risk status.

My patient is very anxious and insists on getting screened. What is the best way to handle this?

The best approach is shared decision-making. Acknowledge her concerns, then clearly explain the evidence from major studies showing the harms (like unnecessary surgery from false positives) outweigh the benefits (no proven reduction in mortality). Frame the decision not to screen as an evidence-based way to keep her safe from iatrogenic harm. Focusing on symptom awareness is a positive, proactive alternative.

What about using the CA-125 blood test for screening in this population?

Like ultrasound, the CA-125 blood test is also not recommended for screening average-risk women. It has a low specificity, meaning it can be elevated due to many benign conditions (like fibroids or endometriosis), leading to a high rate of false positives. Major guidelines from the ACR and USPSTF advise against using CA-125 for routine ovarian cancer screening in the general population.

If I’m not ordering screening, what symptoms should I counsel my postmenopausal patients to watch for?

You should advise patients to seek medical attention if they experience persistent (daily or near-daily for more than a few weeks) symptoms such as abdominal bloating, pelvic or abdominal pain, difficulty eating or feeling full quickly, and urinary symptoms like urgency or frequency. While these symptoms are often caused by benign conditions, their persistent and new onset warrants a diagnostic evaluation.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 26, 2026